FDA Approves Mylan’s Generic of Precose

Mylan Inc. Jan. 18 announced that its subsidiary, Mylan Pharmaceuticals Inc., has received final approval from the Food and Drug Administration for its generic version of Bayer’s Precose (acarbose) 25 mg, 50 mg, and 100 mg tablets.

Precose is a treatment to be used with diet and exercise to improve glycemic control in adults with type 2 diabetes, the Pittsburgh-based company said. The product is available for immediate shipment.

Acarbose tablets had U.S. sales of approximately $23 million for the 12 months ending Sept. 30, 2010, according to IMS Health.